Viralgen and Axovia Therapeutics enter partnership, target retinal dystrophy in Bardet-Biedl Syndrome

News
Article

The lead gene therapy candidate, AXV-101, is expected to enter clinical development in mid-2025

An illustration of a genetic DNA helix with a red target on it. Image credit: ©Елена Бутусова – stock.adobe.com

Viralgen and Axovia are developing an AAV9-based gene therapy for retinal dystrophy in patients with Bardet-Biedl Syndrome (BBS). Image credit: ©Елена Бутусова – stock.adobe.com

Viralgen and Axovia Therapeutics are partnering to advance the development and manufacture of an AAV9-based investigational gene therapy aimed at treating retinal dystrophy in patients with Bardet-Biedl Syndrome (BBS). The collaboration will give patients access to a dynamic investigational treatment with the potential to stop photoreceptor cell death and retinal degeneration, as well as halt vision loss.

According to a press release, the two companies will work together by using the codon-optimised BBS1 AAV9 vector to minimise the vision loss caused by the genetic defects in the BBS1 gene. The therapy will also be manufactured at Viralgen’s facility, capitalising on the company’s expertise in AAV and using the Pro10 cell line and manufacturing platform.

“As Axovia advances its pipeline of potential therapies addressing the genetic causes of blindness towards the clinic, we want to ensure we have appropriately scaled AAV manufacturing to support this effort, and are very happy to have partnered with Viralgen as our [Contract Development and Manufacturing Organisation],” said Victor Hernandez, co-founder and chief scientific officer. “Our lead programme, AXV-101, which is being developed to address retinal dystrophy associated with Bardet-Biedl Syndrome (BBS), is expected to enter clinical development in mid-2025, and we believe this partnership will ensure fast and efficient development as we seek to advance this therapy toward patients as soon as possible.”

“We are delighted to partner with Axovia and bring in our AAV manufacturing expertise. We are committed to supplying quality vectors and timely supply with the goal of providing disease-modifying treatment for patients affected by BBS1-related retinal dystrophy,” Jimmy Vanhove, CEO of Viralgen, said.

Reference

Viralgen and Axovia Partner to Manufacture an Investigational Gene Therapy for Retinal Dystrophy in Bardet-Biedl Syndrome (BBS) patients. Viralgen. Published January 22, 2025. Accessed January 27, 2025. https://viralgen.com/news/viralgen-and-axovia-partner-to-manufacture-an-investigational-gene-therapy-for-retinal-dystrophy-in-bardet-biedl-syndrome-bbs-patients

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.